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RESUMEN 
Se ha elaborado un modelo para el estudio de la cinética y equilibrio de las reacciones antígeno-
anticuerpo implicadas en el radioinmunoanálisis (RIA) de doble anticuerpo correspondiente al Péptido 
C. Se pretende caracterizar la influencia de las concentraciones iniciales de antígeno marcado (M) y no 
marcado (Q) sobre la formación del inmunocomplejo (PM) al segundo anticuerpo (J) inmovilizado 
sobre una bola. Se realizan 30 experiencias para el estudio del efecto de las variables antes 
mencionadas. Los resultados obtenidos son concordantes con el modelo propuesto.  
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ABSTRACT 
A model has been produced for the kinetic and equilibrium study of antigen-antibody reactions in the 
radioimmunoassay (RIA) of C-Peptide double antibody. The aim is (1) to characterise the influence of 
initial concentrations of labelled (M) and unlabelled (Q) antigen and that of the initial concentration of 
the antibody in solution (P), and (2) to study the binding of the immunocomplex (PM) to the second 
antibody (J) immobilised on a bead, and the replacement of M by Q in the PMJ immunocomplex. In 
order to study the effect of such variables, 44 experiments were conducted. The results are in line with 
the model proposed.
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NOMENCLATURE 
P = antibody in solution,  Q = unlabelled antigen,  M = 125Iodine-labelled antigen,  J = second antibody 
coated on plastic beads,  P0, M0 , Q0 = initial concentrations in arbitrary units,  PQ, PQJ = non-
radioactive immunocomplexes, PM, PMJ = radioactive immunocomplexes, [P], [Q], [M], [PQ], 
[PM],[PQJ], [PMJ] = concentrations in mol/L, [J] = concentration of vacant biding sites in antibody J, 
Z = cpm activity in each tube after reaction (Z=Zsp+Z0). The tables include a sub-index indicating the 
experiment number. Zsp = cpm activity from the radioactive immunocomplex corresponds to specific 
binding. Z0 = value of Z at t=0, corresponds to non-specific binding. Z∞ = value of Z obtained at t 
infinity. Ze = value of Z at equilibrium (Ze=Z∞-Z0), t = time in minutes, k = rate constant, K = 
equilibrium constant, r = correlation coefficient. 
1. INTRODUCTION 
C-peptide is a polypeptide (31 amino acid residues) with a relative molecular mass (RMM) of 3018 
Dalton. It is part of the proinsulin molecule and has the following structure: B chain – Arg – Arg -C-
peptide – Lys – Arg – A chain. 
In the pancreatic -cells, proinsulin is enzymatically cleaved into insulin (A chain and B chain) and 
the C-peptide molecule. Both are simultaneously secreted in equimolar concentrations into blood. 
Insulin has a rather short half-life -5 minutes- while the half-life of C-peptide is 30 minutes. Therefore, 
the molar ratio between C-peptide and insulin in peripheral blood ranges between 3:1 and 5:1. The 
main degradation site for C-peptide is the kidney. Consequently, patients with renal dysfunction have 
a longer half-life and higher basal values. Among other reasons, its determination is indicated in the 
study of pancreatic reserves in individuals with diabetes and pancreatectomy patients, and in 
insulinoma diagnosis.  
Radioimmunoassay (RIA) is used in C Peptide assessment. It is a competitive technique in which the 
antigen molecule to be determined (Ag) competes with a radioactive tracer (labelled antigen: Ag*) in 
order to bind to a specific antibody (Ab) that binds to both antigens until equilibrium is reached, in 
which circumstance both immunocomplexes -the radioactive one and the non-radioactive or “cold” 
one- can coexist1: 
Ag + Ab + Ag* ⇔ (Ag ⎯ Ab) + (Ag ⎯ Ab)*
By keeping tracer (Ag*) and antibody (Ab) quantities constant, the higher or lower proportion in the 
immunocomplexes formed will solely depend on the amount of cold antigen (Ag) in the sample to be 
analysed. 
If the tracer behaves similarly when bound or in solution, then the separation of the bound and free 
fractions is essential. In our case, separation is accomplished by fixation on a second antibody coated 
on a plastic bead. 
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Kinetics and equilibrium in antigen-antibody reactions are determining factors of the rapidity, 
analytical range, and reliability2 of immunoanalytical techniques. Likewise, the search for more 
reliable faster immunoassays is one of the main development areas in this field. This has caused the 
overall process to be progressively automated, from sample handling to statistical assessment of 
results (3-6). Yet, despite the large number of immunoanalytical systems developed in recent years, 
very few of them include kinetic analysis. 
Several models have been proposed for the adjustment of the kinetic data on association and 
dissociation reactions. In our previous research3,4,5,6,7,8, different characteristics related to the kinetics 
of antigen-antibody reactions used in analytical techniques were studied, incorporating radioactivity as 
a measurable magnitude.  
Equilibrium data analysis is broadly used in the determination of the ability of a substance to bind to 
one or several receptor populations. However, as pointed out by Weber9, the detection of two binding 
sites by such assays requires the ligand to have very different affinity for both binding sites. 
Zúber et al.10 analysed the kinetics of a new homogeneous immunoassay based on fluorescent energy 
detection, fitting the obtained values to three models: monomolecular, hyperbolic, and Gompertz; they 
drew the conclusion that the best correlation is reached in the first model. Later on, the same authors11 
realized that experimental data fit in with the monomolecular or descriptive model already used in the 
previous research, good overall correlation being found -not so good in the first portion of the curve 
possibly due to an inflection point unforeseen by the equation used. 
Through continuous flow immunoassays, Rabbany et al.13 analysed the dissociation kinetics of the 
complex labelled antigen – immobilised antibody in the absence of unlabelled antigen. In another 
paper, Rabbany et al. (13) studied displacement kinetics for an immunoassay in trinitrotoluene (TNT) 
continuous flow against its antigen immobilised on a porous membrane. The latter assay type suggests 
that lower flow rates produce a longer interaction between the injected unlabelled antigen and the 
labelled antigen - antibody complex, and consequently a greater labelled antigen displacement, more 
intense signals being recorded. 
2. GENERAL MODEL  
2.1. Influence of the initial labelled antigen concentration on reaction kinetics 
Radioactive immunocomplex  formation: 
            k’D
P + M  + J ⇔ PMJ 
                  kI 
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its equilibrium constant is:       
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[ ] [ ] [ ] I
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JMP
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The above reaction can be assigned the following mechanism: 
k1
P + M ⇔ P····M 
k-1
 
k2
P·····M ⇔ PM 
             k-2
 
 k3
PM +J  ⇔ PMJ 
              k-3 
where the first stage consists of the diffusion approximation of the reacting molecules until the 
encounter complex (P····M) is formed. It is considered reversible, since the encounter complex can be 
dissociated, but this is not very likely due to the cage effect (22). At the second stage, the intermediate 
immunocomplex (PM) is formed, and in the third stage the binding of the immunocomplex to the 
second antibody immobilised on a bead takes place. 
Matter conservation requires: 
[ ] [ ] [ ] [ ] [ ]PMJPMM····PPP0 +++=  
 
[ ] [ ] [ ] [ ] [ ]PMJPMM····PMM0 +++=  
 
By derivation of the first of the previous equations, we obtain: 
[ ] [ ] [ ] [ ]
dt
PMJd
dt
PMd
dt
M····Pd
dt
Pd0 +++=  
Let us assume stage 1 to be the slowest one -hence a rate limiting stage-, and let us assume that P····M 
and PM are stationary, which means their concentrations are very small, then the following can be 
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written: 
[ ] [ ]
dt
PMJd
dt
Pd0 +=  
The overall reaction rate is given by: 
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The value of [J] corresponds to the concentration of vacant binding sites on the antibody coating the 
bead. If we assume it to be in excess, [J] can be considered constant; by simplifying and calling k’D 
and kI the constants groups ruling the overall direct and reverse processes, then a differential rate 
equation is obtained in the form 
[ ] [ ] [ ] [ ]PMJkMPk
dt
PMJd
ID
' ⋅−⋅⋅=  
The terms in square brackets represent mol·L-1 concentrations. They must be multiplied by the 
adequate factor to convert them to the practical units used since the experimental data are radioactivity 
measurement. Then, the equation is transformed into: 
Zspk)ZspM()ZspP(k
dt
dZsp
I00D ⋅−−⋅−⋅=  
By integration, it takes the following form: 
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=  (Eq.1) 
By assuming 1
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excess in relation with the antibody), then the process behaves as an apparently irreversible process, 
and Eq.1 for two binding site types transforms into: 
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(Eq.2) 
2.2. Influence of initial labelled and unlabelled antigen concentrations on reaction kinetics 
If unlabelled peptide Q competes with M in the binding to the antibody, the following process will 
take place simultaneously: 
               k′′D 
 P +Q + J ⇔  PQJ 
          k′I
its equilibrium constant being   
[ ][ ] [ ] [ ] I'DQ' k
"k
JQP
PQJK =⋅⋅=  
In line with the previous descriptions, and by calling KM and KQ the products of K’M · [J ] and K’Q · [J], 
the conservation conditions are now: 
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By transforming the concentrations into activities and taking into account that Ze is the cpm value 
corresponding to [PMJ] and simplifying, then: 
cQbM
MP
Z
00
00
e +⋅+
⋅=  (Eq.3) 
By substituting the value of Ze obtained by Eq.3 in Eq.2, we have (Eq.4) 
2.3. Equilibrium equations 
These are obtained from rate equations by making time tend to infinity. By doing this, exponential 
terms containing such a variable disappear., Additionally the unspecific activity is subtracted. 
3. MATHERIAL AND METHODS 
3.1. Reagents 
The reagents used belong to the RIA-coat® C-Peptid kit, manufactured by Byk-Sangtec Diagnostica 
GMBH & Co.KG. The kit includes: 
- A polyclonal antiserum obtained by immunising goats with synthetic human C-peptide 
- A second monoclonal antibody (mouse anti goat) coated on a plastic bead 
- 125I-C-peptide: a vial with lyophilised labelled C peptide 
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-Unlabelled C peptide vials in different concentrations, with which different solutions were prepared, 
0, 0.533 and 5.917 ng/mL being the final concentrations for the determination of the influence of 
initial labelled and unlabelled antigen concentrations, and 1, 3, 10 and 30 ng/mL for the study of the 
labelled antigen displacement resulting from the addition of the unlabelled antigen. 
3.2. Instrumentation 
LKB Gammamaster Automatic Gamma Counter, fitted with a computer with a Riacalc programme. 
3.3. Computer programme 
Statistica (Copyright© StatSoft, Inc.1993). It allows the fitting of experimental data using specific 
non-linear regression equations, and the production of the corresponding tables. As a statistical 
criterion for equation selection in the different models, AIC (Akaike’s Information Criterion) was 
observed; it can be expressed as follows: AIC = N·lnS + 2·P, where N is the number of points, S the 
addition of the squares of the residuals, and P the number of parameters in the equation. The equation 
with the lowest AIC in the fitting must be chosen (See Results) No sé si este cambio sera posible. 
3.4. Experimental procedure  
30 experiments were performed in which were studied the influence of the influence of initial 
concentrations of labelled (M0) and unlabelled (Q0) C Peptide on reaction kinetics and equilibrium. 
Tube series were prepared with 100 µL of each of the different labelled and unlabelled antigen 
solutions, together with 100 µL of antibody solution and a bead in each tube. They were left to react in 
agitation for different time periods, after which they were washed, eliminating the liquid and leaving 
the bead in order to measure its radioactivity on the counter. One tube from each series was left to 
react for 24 hours, this being considered infinite time and therefore corresponding to the value at 
equilibrium. 
4. RESULTS AND DISCUSSION 
4.1. Previous Experiment 
In this experiment tubes were added labelled C peptide (M) and an antibody-coated bead (J), the 
antibody in solution not being added (P). No bead-bound radioactivity was found, this indicating that 
it is the PM immunocomplex which actually binds to antibody J, and therefore the overall process 
includes the formation of the PM immunocomplex, followed by its binding to the J antibody coating 
the bead. 
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4.2. Influence of initial labelled (M0) and unlabelled (Q0) antigen concentrations on reaction 
kinetics and equilibrium 
Table 1. Influence of M0 y Q0 
Table 1 shows that for a given value of Q, with increasing concentration of M, increases the amount of 
radioactive immunocomplex for all times. The influence of unlabeled antigen Q, increasing its 
concentration, reduces the amount of radioactive immunocomplex for all time, which can be attributed 
to the partial occupation of the antibody binding sites by Q. 
The data in Table I have been fitted to Eq.4 in the General Model, save for the Z0 unspecific activity 
term, which has been taken as equal to p·M0. These are its parameters and coefficients: 
P01 b c kd1·104 P02 i j kd2·104 p r AIC 
42610 545926 69245 0.001389 16280 302253 20135 0.000283 0.006 0.995 3470 
t        M0      (Q)0
(min) (cpm) (ng/mL)
Z1 247,5 11 81,5 2760,7 4957,2 7711,1 8515,9 14364,5 15929,0 0,000
Z2 29,1 873,7 1972,4 3920,8 5752,0 6887,5 11750,0 12790,5 0,000
Z3 112,8 681,4 1715,5 2863,1 4203,1 5103,7 8866 ,6 9463,7 0,000
Z4 154,1 535,3 1190,5 1978,0 2431,0 3448,7 5819 ,7 6310,6 0,000
Z5 213,4 438,2 530,5 881,2 1391,3 1927,1 2952 ,9 3409,3 0,000
Z6 274,0 10 23,5 2337,4 3132,2 4431,0 4971,6 6964 ,6 15929,0 0,533
Z7 47,4 778,9 1727,1 2810,2 3840,5 4864,0 5506 ,9 12790,5 0,533
Z8 107,3 597,2 1384,9 2062,8 2731,5 3018,1 4335 ,6 9463,7 0,533
Z9 181,7 519,7 913,0 1495,5 1995,1 1965,9 2968 ,5 6310,6 0,533
  Z10 215,1 407,9 384,9 593,9 1057,0 1126,3 1475 ,1 3409,3 0,533
  Z11 230,0 824,5 1121,7 1329,2 1622,3 1644,6 1483 ,5 15929,0 5,917
  Z12 17,7 519,7 1090,8 1320,0 1293,5 1430,0 1222 ,5 12790,5 5,917
  Z13 56,1 477,7 815,7 893,0 800,1 856,0 774,4 9463,7 5,917
  Z14 136,4 440,5 596,5 709,0 671,5 672,6 521,2 6310,6 5,917
  Z15 199,1 361,0 215,9 250,1 392,6 431,1 266,6 3409,3 5,917
Z1 6 155,5 12 10,5 3075,0 5287,5 7286,1 9494,1 14602,5 17463,0 0,000
Z1 7 0,00 845,8 2292,1 4297,8 6702,5 7310,0 12756,5 14146,0 0,000
Z1 8 35,2 695,7 1683,5 3130,8 4709,7 5193,4 9363 ,6 10352,0 0,000
Z1 9 17,2 396,8 1116,0 2096,5 3063,4 3781,6 6132 ,8 7036,0 0,000
Z2 0 30,3 262,0 497,4 825,2 1612,1 1964,0 3228 ,6 3635,0 0,000
Z2 1 88,5 10 20,5 2115,1 3663,9 4735,9 5504,7 6851 ,3 17463,0 0,533
Z2 2 56,5 618,5 1746,4 2876,8 3468,5 3786,0 5539 ,4 14146,0 0,533
Z2 3 22,0 518,5 1178,4 1897,5 2716,0 3008,4 4273 ,4 10352,0 0,533
Z2 4 7,3 370,7 947,0 1391,0 1929,1 2116,7 3094 ,5 7036,0 0,533
Z2 5 28,0 191,6 352,9 577,4 934,6 1128,3 1482 ,9 3635,0 0,533
Z2 6 76,5 335,5 509,1 754,6 966,7 918,7 1113 ,5 17463,0 5,917
Z2 7 0,00 145,1 351,5 568,6 697,5 769,5 955,5 14146,0 5,917
Z2 8 20,4 147,5 351,2 405,0 368,9 391,8 702,3 10352,0 5,917
Z2 9 0,00 8 9,0 245,0 421,0 371,0 419,4 437,5 7036,0 5,917
  Z30 18,9 6 4,6 41,1 37,7 125,0 136,4 196,2 3635,0 5,917
∞0 10 30 60 120 180
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which can be reduced to: 
( )( )[ ] ( )( )[ ] 002D
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0
01D
0
0 M'p'jQ'ktexp1
'jQ
Me'cQ'ktexp1
'cQ
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⋅=  
(Eq.4a) 
its parameters and coefficients being: 
a c’ k’d1 e j’ k’d2 p’ r AIC 
0.0246 0.0908 0.201 0.1196 0.1938 0.01681 0.00529 0.996 3432 
Eq.4a suggests an apparently irreversible biexponential behaviour attributable to the bonding with two 
binding site types. The apparent kinetic parameters are independent from M, which can be explained 
by admitting that the labelled reagent is in default with respect to the P antibody in solution. The 
influence of M is seen in the equation as only affecting equilibrium terms (they precede those between 
square brackets). The amount of labelled antigen bound at equilibrium is directly proportional to M. 
The influence of the unlabelled antigen (Q) is seen in the fact that it appears in the kinetic and 
equilibrium terms. When Q0 is increased, the apparent rate constant rises, this causing t1/2 to decrease. 
This can be explained by admitting that, as a consequence of the partial occupation of the antibody's 
binding sites by Q, less time is needed to occupy half of them.  The amount of labelled antigen bound 
at equilibrium decreases for the same reason. As an overall result, Z diminishes for all times. 
The consistency between the observed values (Table I) and those calculated by Eq.4a is shown in 
Figure 1. 
 
Fig.1. Observed Values (Tabla 1) vs. Predicted Values (Ec.4a) 
Observed Value = 15.1 + 0.997·Predicted Value   r = 0.996 
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The results at infinite time, corresponding to equilibrium, fit in with the following equation 
998.0r
1938.0Q
M1196.0
0908.0Q
M0246.0Z
0
0
0
0
e =+
⋅++
⋅=  
5. CONCLUSIONS 
1. In the formation of the PMJ immunocomplexes, an apparently irreversible biexponential 
behaviour is found, corresponding to two binding site types. 
2. As a result of an increased concentration, the influence of the labelled antigen shows in an 
increased amount of radioactive immunocomplex at all times, while the apparent rate and dissociation 
equilibrium constants remain unaltered. 
3. The influence of the unlabelled antigen is seen in the fact that, when its concentration is 
increased, the amount of radioactive immunocomplex drops for all times, which can be put down to 
the partial occupation, by Q, of the antibody’s binding sites, whereas the apparent rate and dissociation 
equilibrium constants rise. 
4. Equilibrium data do not allow us to distinguish single site from double site binding models. 
However, a distinction was possible between both models when kinetic data were used. 
5. Experimental results were satisfactorily fitted to the theoretical model. 
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